Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the phase I clinical study (study code: JSKN027-101) of JSKN027, an independently developed ...

Key combination for the treatment of Small Cell Lung Cancer MADRID and CAMBRIDGE, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, ...

Nanjing Leads Biolabs Co., Ltd. ('Leads Biolabs' or the 'Company,' Stock Code: 9887.HK) announced on March 6, 2026 that the ...

Egret Therapeutics, Inc. ("Egret"), a clinical-stage biotechnology company developing novel immune-modulatory therapies for secondary inflammation following traumatic and ischemic disorders, today ...

(UroToday.com) The 2026 European Association of Urology (EAU) annual meeting featured a high-risk non-muscle invasive bladder cancer session and a presentation by Dr. Dingwei Ye discussing results of ...

JS207, Junshi Biosciences’ independently developed recombinant humanized anti-PD-1/VEGF bispecific antibody, has demonstrated promising anti-tumor activity and a manageable safety profile in both ...

A protein already targeted by FDA-approved cancer drugs may also help the body fight influenza, according to new research from The Jackson Laboratory (JAX). Published in Cell Reports, the study found ...

A protein already targeted by FDA-approved cancer drugs may also help the body fight influenza, according to new research ...

Immune checkpoint inhibitors targeting PD-1 and PD-L1 have revolutionized cancer therapy, delivering long-term survival benefits in several malignancies. However, nearly half of patients show limited ...

CERRITOS, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- Liminatus today announced plans to initiate a Phase 1 clinical trial evaluating IBA101, a next-generation CD47-blocking monoclonal antibody ...

A newly discovered cancer trick that weakens immunotherapy may be stopped by everyday statins.